Loren Pickart, who isolated GHK-CU in 1973, shows that the peptide increases production of Type I and Type III collagen while simultaneously upregulating matrix metalloproteinases, the enzymes that break down old, damaged collagen
Dosing matters because GHK-CU operates through gene expression modulation
Together, these peptides create a potent healing environment in the body, making them especially effective for treating sports injuries, post-surgery recovery, and chronic pain conditions
Interest in DSIP research declined over time, partly because of mixed clinical findings and partly because peptide research funding shifted toward other compounds
Tetrahydrobiopterin-dependent preservation of nitric oxide-mediated endothelial function in diabetes by targeted transgenic GTP-cyclohydrolase I overexpression